ClinicalTrials.gg
RecruitingNCT06800313Updated Nov 3, 2026

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

A Phase 1/2 interventional study of JNJ-101556143 Formulation 1 and JNJ-101556143 Formulation 2 in Metastatic Prostate Cancer, sponsored by Janssen Research & Development, LLC. Recruiting at 18 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.
Updated Sep 25, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
190
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 88 studies in Prostatic Neoplasms by Johnson & Johnson — 9 open to participants now, 23 under way, 9 of them phase 3. Prostatic Neoplasms · Johnson & Johnson.

Planned enrollment
20th of 68
190 · median 82
Started
2025
with 2 others
Phase 1/2
4 of 88
1 open now
Primary completion
2028-08
later than 19 of 22 live
Registered
82nd of 88
by date

Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 20th largest by planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2025, is one of 4 in phase 1/2, reaches primary completion later than 19 of the 22 other live ones, and was the 82nd registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 88 studies in Prostatic Neoplasms by Johnson & Johnson are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Prostatic Neoplasms by Johnson & Johnson, or all of them as a file.
02

Study summary

Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

03

Conditions studied

  • Metastatic Prostate Cancer

Keywords

  • Prostate Cancer
  • RIPTAC
  • HLD-0915
  • Genital Neoplasms, Male
  • Urogenital Neoplasms, Male
  • Genital Diseases, Male
  • Urogenital Diseases, Male
  • Neoplasms, Glandular and Epithelial
  • Prostatic Neoplasms
  • Prostate Adenocarcinoma
  • Hormone Sensitive, Castrate Resistant
  • Metastatic Castrate Resistant Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Patients must meet the following criteria to be eligible study participation:

Key Inclusion Criteria:

All Study Arms (Phase 1 Part 1 \& 2, Phase 2 Part 1, Part 2A, 2B, 2C \& 2D):

Males ≥ 18 years old Histological, pathological, and/or cytological confirmation of prostate adenocarcinoma Adequate hematological, renal, and hepatic function. Able to swallow oral medication

mCRPC Arms: (Phase 1 Part 1 \& 2, Phase 2 Part 1): Prior orchiectomy or ongoing androgen-deprivation therapy and a castrate level of serum testosterone Progressive mCRPC defined as having demonstrated PSA progression on the prior regimen

SOAR Arm (Phase 2 Part 2A) mHSPC with distant disease based on conventional imaging PSA ≥0.2 ng/mL, following treatment with next generation ARPI for at least 180 days and up to 365 days No evidence of radiographic or PSA progression while receiving ARPI

mHSPC arms (Phase 2 Part 2B, 2C \& 2D) serum testosterone >150ng/ml mHSPC with distant metastatic disease based on conventional imaging and PSA >2.0 ng/mL

Key Exclusion Criteria:

All arms (Phase 1 Part 1 \& 2, Phase 2 Part 1, Part 2A, 2B, 2C \& 2D):

Has experienced a recent major bleed or has a known bleeding disorder Tumors exhibiting neuroendocrine or small cell carcinoma component by histopathology Receiving continuous at prednisone-equivalent dose of >10 mg/day Prior or ongoing significant medical condition

mCRPC arms: (Phase 1 Part 1 \& 2, Phase 2 Part 1): Has received systemic anti-cancer therapy or drugs within 2 weeks prior to first dose of study drug with certain exceptions requiring longer

SOAR arm (Phase 2 Part 2A) Has received any prior cytotoxic chemotherapy for prostate cancer

mHSPC arms (Phase 2 Part 2B, 2C \& 2D) regional pelvic lymph node disease only

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
190 participants (estimated)

Study arms

  • Experimental
    JNJ-101556143 Phase 1 Part 1 - Dose Escalation

    Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

    Drug: JNJ-101556143 Formulation 1

  • Experimental
    JNJ-101556143 Phase 1 Part 2 - Formulation Exploration

    Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

    Drug: JNJ-101556143 Formulation 1 · Drug: JNJ-101556143 Formulation 2 · Drug: JNJ-101556143 Formulation 3

  • Experimental
    JNJ-101556143 Phase 2 Part 1 - Dose Optimization

    Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

    Drug: JNJ-101556143 Formulation 1

  • Experimental
    Phase 2 Part 2A - SOAR

    Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

    Drug: JNJ-101556143 Formulation 1

  • Experimental
    Phase 2 Part 2B - HSPC Expansion

    Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

    Drug: JNJ-101556143 Formulation 1

  • Experimental
    Phase 2 Part 2C - HSPC Expansion

    Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

    Drug: JNJ-101556143 Formulation 1

  • Experimental
    Phase 2 Part 2D - HSPC Expansion

    Treatment cycle consists of 21 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

    Drug: JNJ-101556143 Formulation 1

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency of dose-limiting toxicities (DLTs)

    Time frame: 21 days

  2. Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline

    Time frame: 21 days

  3. Phase 1 Part 2 (formulation exploration) relative bioavailability

    Time frame: 22 days

Secondary outcomes

  1. PK Parameters

    Time frame: 21 days

  2. Change in PSA over time

    Including PSA50 and PSA90 response

    Time frame: 21 days

  3. Objective Response Rate (ORR)

    Per RECIST in evaluable patients

    Time frame: 63 days

  4. Duration of Response (DOR)

    Time frame: 21 days

  5. Radiographic Progression-Free Survival (rPFS)

    Time frame: 63 days

  6. Time to Response (TTR)

    Time frame: 63 days

07

Study locations

18 of 18 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Aug 2028, 42 months after the start.

Of 96 industry-sponsored phase 1/2 interventional studies under Prostatic Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 35. This study's planned 42 months is below that.

Counting every sponsor, half of 210 studies reached it within 61 months; a quarter within 30 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Jul 2028 → Aug 2028 and completion Jul 2028 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2025
First posted
Jan 30, 2025
StartActual
Feb 6, 2025
Primary completionEst.
Aug 17, 2028was Jul 2028
CompletionEst.
Aug 17, 2028was Jul 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 11, 2028→Aug 17, 2028
Sep 25, 2026
Study completion
Jul 11, 2028→Aug 17, 2028
Sep 25, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 25, 2026
    Primary completion Jul 11, 2028→Aug 17, 2028
    Study completion Jul 11, 2028→Aug 17, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06800313
Responsible party
Sponsor
First posted
Jan 30, 2025
Start date
Feb 6, 2025
Primary completion
Aug 17, 2028 (estimated)
Completion
Aug 17, 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915

Start the discussion